Conversely, one study reported opposing findings, suggesting that miR-184 may act as a tumour promoter by enhancing tolerance to epidermal growth factor receptor (EGFR)-targeted therapies, thereby facilitating tumour progression when such treatments are inhibited [31]. This evidence concerns the gene EGFR and neoplasm.